Dr. Steven T. Rosen Joins Cizzle Bio as Scientific Advisor
Cizzle Bio is proud to welcome Dr. Steven T. Rosen, a distinguished hematologist and oncologist, as our newest Scientific Advisor. With an extraordinary career spanning decades in cancer research and treatment, Dr. Rosen’s expertise will be invaluable as we continue to innovate in cancer diagnostics.
Dr. Rosen has worked closely with Cizzle Bio’s CEO Bill Behnke for many years in the for-profit and nonprofit sectors; they spent 9 years together on the National Board for the Leukemia and Lymphoma Society and they currently sit on ASCO’s Conquer Cancer Board.
A Legacy of Excellence
Dr. Rosen’s illustrious career includes key roles in cancer research, education, and clinical care:
Executive Vice President & Director Emeritus of Beckman Research Institute at City of Hope.
Former Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine.
Principal investigator for numerous grants, including those from the National Cancer Institute (NCI), Leukemia & Lymphoma Society (LLS), and Multiple Myeloma Research Foundation.
With more than 500+ scientific publications, Dr. Rosen has made significant contributions to understanding and treating hematologic malignancies and developing experimental therapeutics.
Recognized Leadership in Oncology
Dr. Rosen’s commitment to advancing oncology has earned him numerous accolades:
Recipient of the Giants of Cancer Care Award (2021).
Fellow, Royal College of Physicians (2023).
Honored with the Excellence in Scientific Service Award by the Leukemia & Lymphoma Society (2023).
As the editor-in-chief of Cancer Treatment and Research, Dr. Rosen continues to shape the future of cancer care globally.
A Shared Commitment to Cancer Innovation
“We are excited to have Steve Rosen, MD as part of our team. Steve and I both serve on The ASCO Conquer Cancer Board and spent nine years on the National Board for the Leukemia & Lymphoma Society. His work at City of Hope has been second to none, and his contributions to Cizzle Bio early on have been extremely helpful and insightful.” — Bill Behnke, CEO
Driving Cizzle Bio’s Mission Forward
Dr. Rosen’s extensive experience aligns perfectly with Cizzle Bio’s mission to revolutionize early cancer detection. His guidance will strengthen our focus on advancing biomarker-based diagnostics to improve patient outcomes worldwide.
A Future of Innovation and Impact
Dr. Rosen joins us at a pivotal moment as we expand our cutting-edge diagnostic tools, including the CIZ1B Biomarker Test for early lung cancer detection and the upcoming DEX-G2 Gastric Cancer Test. His insights will be instrumental in accelerating research, fostering collaborations, and ensuring the highest standards in clinical applications.
Join Us in Welcoming Dr. Rosen
We are excited to have Dr. Rosen’s unparalleled expertise on our team as we continue to innovate and transform cancer care. Together, we are building a future where early detection saves lives.
